Biotech Stock Mailbag: Oncothyreon, Amag, Keryx Hate Mail
Biotech columnist Adam Feuerstein responds to biotech stock questions posed by his Twitter followers.
No Wow Factor in Jobs Report
An in-line jobs report is not enough to overcome a weakened consumer, says Professor Peter Morici.
The Next Big Thing in Biotech: Cancer Drug Stocks
Senior columnist Adam Feuerstein explains why cancer drug stocks are the next big thing in biotech.
E-books are growing in both popularity and sales, but some literary classics are stuck on the shelf. 8 Stocks Billionaire John Paulson Loves
Here's a look at eight stocks that Paulson & Co. bought in the fourth quarter. The 10 Richest Colleges in America
Ranked by endowment, these colleges are putting their vast fortunes toward very different uses. Why Cisco Benefits From Apple's iPad (Update 1)
Cisco welcomes the launch of Apple's new iPad, as well as the slew of Android-based tablets flooding the market. Starbucks to Challenge Keurig With 'Verismo': Hot Trends
Starbucks is launching its own single-cup brewer later this year, directly competing with Green Mountain Coffee's Keurig machines. Stock Futures Rise on February Jobs Increase
Stock futures are pointing to a higher open Friday as the February jobs report beat expectations. 3 Shorted Stocks Too Cheap to Sell
Here's a look at 3 shorted stocks that may be too cheap to sell if acquirers weigh bids. (Stocks include FSLR, BBY, VECO)
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV